Caracterización de la expresión de galectina-3 mediante inmunohistoquímica en lesiones intraepiteliales de glándula mamaria de perras sin evidencia de tumor
Characterization of galectin-3 expression by immunohistochemistry in mammary intraepithelial lesions in bitches without evidence of tumor
DOI:
https://doi.org/10.15446/rfmvz.v66n2.82428Keywords:
perra, galectina- 3, glándula mamaria, carcinogénesis (es)dog, galectin-3, mammary gland, carcinogenesis (en)
Downloads
Las lesiones intraepiteliales (LIEs) son anormalidades morfológicas locales de los ductos
y los lobulillos de la glándula mamaria que incrementan el riesgo de cáncer. Los programas
de detección temprana de cáncer de seno han incrementado la identificación
de LIEs. En este sentido, en perras se ha propuesto las LIEs como modelo comparativo
con humanos. La galectina-3 está involucrada con la progresión del cáncer en mujeres
y hembras caninas pero su papel en el comportamiento biológico de las neoplasias es
contradictorio según la célula de origen. El objetivo de este trabajo fue caracterizar la
expresión de la galectina-3 por medio de inmunohistoquímica en 19 glándulas mamarias
(GM) de seis perras sin evidencia de tumor que contenían 50 tipos de LIEs y 7 carcinomas
invasivos, teniendo en cuenta el porcentaje de células positivas y la intensidad
del color de la inmunoreacción. No hubo inmunomarcación para galectina-3 en las
adenosis, las hiperplasias ductales usuales, la hiperplasia lobular atípica, las lesiones de
células columnares, los carcinomas complejos o las hiperplasias complejas. Un papiloma/
adenoma con hiperplasia de acinos tuvo inmunomarcación multifocal en 11–50% de
las células con moderada intensidad. Dos carcinomas in situ del subtipo lobular (uno
de grado histológico nuclear intermedio y el otro de alto grado) tuvieron marcación en
10% de las células, pero uno tuvo intensidad baja y el otro, intensidad moderada. Los
hallazgos sugieren que el papel de la galectina-3 es poco importante en la iniciación de
las LIEs, pero sugieren que es una proteína de interés en la progresión de estas lesiones
que posiblemente interactúa en el comportamiento biológico de esta enfermedad.
Intraepithelial lesions (IELs) are local morphological abnormalities of the ducts and
lobules of the mammary gland that increase the risk of cancer. Programs of early
detection of breast cancer have improved the identification of IELs. In canines they
have been proposed as a comparative model with human IELs. Galectin-3 is involved
with cancer progression in women and bitches but its role in the biological behavior
of neoplasias is contradictory depending on the source cell. The aim of this study was
to characterize by immunohistochemistry the expression of galectin-3 in 19 mammary
glands (MG) from 6 canines without clinical signs of tumor, containing 50 types of IELs
and seven invasive carcinomas, taking into account the percentage of positive cells and
the intensity of color immunoreaction. There wasn’t any immunostaining for galectin-3
in the adenosis, in the usual ductal hyperplasias, in the atypical lobular hyperplasia, in
the columnar cell lesions, in the complex carcinomas or in the complex hyperplasias. A
papilloma/adenoma with acinar hyperplasia had multifocal staining in 11-50% of the
cells with moderate intensity. Two in situ lobular carcinomas (ISLC) (one of nuclear
intermediate grade and the other of high nuclear grade) had 10% staining cells, but the
intensity was moderate in one of them and low in the other. Findings suggest that the
role of galectin-3 is unimportant in the initiation of IELs, but also that it is a protein
of interest in the progression of the lesions and that it possibly acts in the biological
behavior of the disease.
References
Antuofermo E, Miller MA, Pirino S, Xie J, Badve S, Mohammed SI. 2007. Spontaneous mammary intraepithelial lesions in dogs–A model of breast cancer. Cancer Epidemiol Biomarkers Prev. 16(11): 2247-2256. Doi: 10.1158/1055-9965.EPI-06-0932.
Caicedo JA, Iregui CA. 2014. Intraepithelial Lesions (IELs) in mammary glands of dogs without clinical evidence of tumors. Bogotá (CO): SA. LCPG Presentations in ACVP&ASVCP 2014 Concurrent Annual Meeting. Atlanta – Georgia, USA (November 10th 2014).
Caicedo JA, Martinez N, Iregui C. 2015. Stromal changes within in situ carcinoma and early invasive carcinomas in mammary gland of female dogs without clinical signs of mammary tumor: histopathologic study. Presented at: ACVP/ ASVCP/STP Annual Meeting; October 18th, 2015; Minneapolis, USA.
Castronovo V, Van Den Brûle FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME. 1996. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 179: 43–48. Doi: 10.1002/ (SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N.
Cay T. 2012. Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Turk Patoloji Derg. 28(1): 1-10. Doi: 10.5146/ tjpath.2012.01090.
Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. 2010. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 12(3): 204. Doi: 10.1186/bcr2577.
Choi YK, Hong SH, Kim BH, Kim HC, Woo HJ, Kim DY. 2004. Immunohistochemical expression of galectin-3 in canine mammary tumours. J Comp Pathol. 131: 242-245. Doi: 10.1016/j.jcpa.2004.02.002.
Dabbs DJ. 2012. Breast Pathology. 1st ed. Saunders Elsevier.
De Oliveira JT, de Matos AJ, Gomes J, Vilanova M, Hespanhol V, Manninen A, Rutteman G, Chammas R, Gärtner F, Bernardes ES. 2010. Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology. 20(11): 1341–1352. Doi: 10.1093/ glycob/cwq103.
Ferreira E, Gobbi H, Saraiva BS, Cassali GD. 2010. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer. 10: 61. Doi: 10.1186/1471-2407-10-61.
Galimberti V, Monti S, Mastropasqua MG. 2013. DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast. 22(4): 431-435. Doi: 10.1016/j.breast.2013.04.010.
Goldschmidt M, Peña L, Rasotto R, Zappulli V. 2011. Classification and grading of canine mammary tumors. Vet Pathology Online. 48(1): 117-131. Doi: 10.1177/0300985810393258.
Hakomori S. 2002. Glycosylation defining cancer malignancy: new wine in an old bottle. PNAS. 99(16): 10231- 10233. Doi: 10.1073/ pnas.172380699.
Honjo Y, Nangia-Makker P, Inohara H, Raz A. 2001. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 7(3): 661-668.
Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL. 2009. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 133: 15-25. Doi: 10.1043/1543-2165-133.1.15.
Lopez‐Garcia MA, Geyer FC, Lacroix‐Triki M, Marchió C, Reis‐Filho JS. 2010. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 57(2): 171- 92. Doi: 10.1111/j.1365-2559.2010.03568.x.
Masood S. 2010. Is it time to retire the term of “in situ carcinoma” and use the term of “borderline breast disease”? Breast J. 16(6): 571-572. Doi: 10.1111/j.1524-4741.2010.01014.x.
Mouser P, Miller MA, Antuofermo E, Badve SS, Mohammed SI. 2010. Prevalence and classification of spontaneous mammary intraepithelial lesions in dogs without clinical mammary disease. Vet Pathol. 47(2): 275-284. Doi: 10.1177/0300985809358603.
Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. 2011. Mucins in the pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 1815(2): 224-240. Doi: 10.1016/j.bbcan.2011.01.001.
Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156(3): 899–909. Doi: 10.1016/S0002-9440(10)64959-0.
Nowak M, Madej J, Dzicgiel P, Lopljszynski W, Rodo A, Ugorski M. 2009. Tumor-associated carbohydrate antigens: sialyl Le(a) and T/Tn antigens in canine mammary tumors. Vet Pathol. 46(2): 222-226. Doi: 10.1354/vp.46-2-222.
O’Malley FP, Pinder SE, Mulligan AM. 2011. Breast Pathology: A volume in the series: Foundations in diagnostic pathology (Expert Consult – Online). 2° ed. Saunders.
Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, Sorlie T, Kristensen VN, Lingjaerde OC, Borresen-Dale AL. 2010. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology. 4(2): 98-118. Doi: 10.1016/j.molonc.2009.12.001.
Rosen P. 2009. Papilloma and related benign tumors. En: Rosen PP, editor. Rosen’s Breast pathology. 3° ed. Philadelphia (USA): Lippincot, Williams & Wilkins. 101-108.
Sassi F, Benazzi C, Castellani G, Sarli G. 2010. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res. 6: 5. Doi: 10.1186/1746-6148-6-5.
Sierra A. 2009. Animal models of breast cancer for the study of pathogenesis and therapeutic insights. Clin Transl Oncol. 11(11): 721-7.
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
License
Copyright (c) 2019 Jahnier Andrés Caicedo Martínez, Carlos Arturo Iregui Castro

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
The authors retain copyright of their work and grant the journal the right of first publication.
Readers are free to copy and redistribute the material in any medium or format under the license terms, provided proper attribution is given, the work is not used for commercial purposes, and no modifications or derivatives are made.



